Deans' stroke musings: Future vaccine may help lower blood pressure long-term

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, May 27, 2015

Future vaccine may help lower blood pressure long-term

And it is even needleless, although you would have to be a rat right now.
http://newsroom.heart.org/news/future-vaccine-may-help-lower-blood-pressure-long-term
Study Highlights

A DNA vaccine helped lower blood pressure for up to six months, reduced tissue damage to the heart and blood vessels associated with hypertension in rats.
If future research shows the vaccine is a viable treatment option in humans, it could improve high blood pressure levels.

DALLAS, May 26, 2015 – A vaccine may one day help lower blood pressure for up to six months, according to new research in the American Heart Association’s journal Hypertension.
The study in rats may eventually provide a novel alternative to treat high blood pressure in people, who would not need to take a pill everyday.
“The potential of a vaccine for hypertension offers an innovative treatment that could be very effective for the control of non-compliance which is one of the major problems in the management of hypertensive patients,” said Hironori Nakagami M.D., Ph.D., study co-author and professor at Osaka University in Japan.
Researchers have designed a DNA vaccine that targets angiotensin II ― a hormone that raises blood pressure by causing blood vessels to constrict. This narrowing can increase your blood pressure and force your heart to work harder.
In the study, researchers immunized hypertensive rats three times at two-week intervals with needleless injections. The vaccine not only lowered blood pressure for up to six months, but also reduced tissue damage to the heart and blood vessels associated with hypertension. There were no signs of damage to other organs such as the kidney or liver.
The DNA vaccine works similar to common ACE inhibitor blood pressure medications which help blood vessels relax and open up, which, in turn, lowers blood pressure. Other types of vaccines have been tested for hypertension (e.g. a peptide vaccine), but didn’t have lasting effects and some had undesirable side effects.
The ultimate goal of an anti-hypertensive vaccine is to achieve perfect blood pressure control by improving drug compliance through the vaccine. In addition, in the developing countries like Africa and south Asia, anti-hypertensive drugs such as ARB (angiotensin receptor blockade) are expensive. A DNA vaccine may provide cheaper and effective anti-hypertensive treatments in such countries, researchers said.
“Further research on this DNA vaccine platform, including increasing the longevity of blood pressure reduction, may eventually provide a new therapeutic option to treat hypertensive patients,” Nakagami said.
The technology can also be applied to generate other vaccines.
Co-authors are Hiroshi Koriyama M.D., Ph.D; Futoshi Nakagami; M.D., Ph.D; Mariana Kiomy Osako, Ph.D; Mariko Kyutoku, Ph.D; Munehisa Shimamura M.D.; Ph.D; Hitomi Kurinami M.D., Ph.D; Tomohiro Katsuya M.D., Ph.D; Hiromi Rakugi M.D., Ph.D; and Ryuichi Morishita M.D., Ph.D. Author disclosures are on the manuscript.
Additional Resources: